AI Engines For more Details: Perplexity Kagi Labs You
Migraine Prophylaxis: Flunarizine is effective in reducing the frequency, severity, and duration of migraine attacks. It is commonly prescribed for individuals with recurrent migraines to prevent the onset of headaches and associated symptoms such as nausea, vomiting, and sensitivity to light and sound.
Vestibular Disorders: Flunarizine is also used to manage various vestibular disorders, including vertigo and Meniere's disease. It helps alleviate symptoms such as dizziness, spinning sensation (vertigo), imbalance, and nausea by stabilizing the inner ear and reducing abnormal sensory input to the brain.
Calcium Channel Blocker: Flunarizine acts as a calcium channel blocker, primarily targeting calcium channels in neuronal membranes. By inhibiting calcium influx into cells, particularly in cerebral and vascular tissues, flunarizine exerts its therapeutic effects, including vasodilation and suppression of neuronal excitability.
Preventive Therapy: Flunarizine is typically used as a preventive therapy rather than an acute treatment for migraine attacks. It is taken on a regular basis, often as a long-term prophylactic measure, to reduce the frequency and severity of migraine episodes over time.
Dosage and Administration: Flunarizine is available in oral tablet form and is usually taken once daily. The dosage may vary depending on the individual's age, medical condition, and response to treatment. It is important to follow the prescribed dosage and instructions provided by a healthcare professional.
Side Effects: Common side effects of flunarizine may include drowsiness, fatigue, weight gain, increased appetite, and gastrointestinal disturbances such as nausea and abdominal discomfort. These side effects are usually mild and transient but may necessitate dose adjustment or discontinuation of the medication in some cases.
Central Nervous System Effects: Flunarizine may cause central nervous system (CNS) side effects, including sedation, depression, and extrapyramidal symptoms such as tremors and dystonia. Patients should be advised to exercise caution when operating machinery or engaging in activities requiring mental alertness until they know how the medication affects them.
Cardiovascular Effects: Flunarizine may rarely cause cardiovascular side effects, including changes in heart rate, blood pressure, and electrocardiogram (ECG) parameters. It should be used with caution in individuals with preexisting cardiovascular conditions, and cardiac function should be monitored periodically during treatment.
Contraindications: Flunarizine is contraindicated in individuals with a history of hypersensitivity to the drug or its components. It should be avoided in patients with severe depression, Parkinson's disease, or a history of movement disorders such as tardive dyskinesia.
Drug Interactions: Flunarizine may interact with other medications, including central nervous system depressants, antihypertensive drugs, and selective serotonin reuptake inhibitors (SSRIs), leading to additive CNS effects or changes in blood pressure. It is important to inform healthcare providers about all medications being taken to avoid potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2 | 0.5 | 3 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.3 | 0.67 |
| Allergic Rhinitis (Hay Fever) | 1.6 | 1.6 | |
| Allergies | 3.5 | 0.6 | 4.83 |
| Allergy to milk products | 0.4 | 0.3 | 0.33 |
| Alopecia (Hair Loss) | 1.4 | 1.4 | |
| Alzheimer's disease | 1.7 | 5 | -1.94 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 2.1 | |
| Ankylosing spondylitis | 2.1 | 1.8 | 0.17 |
| Anorexia Nervosa | 0.3 | 2.1 | -6 |
| Antiphospholipid syndrome (APS) | 1.6 | 1.6 | |
| Asthma | 0.7 | 0.6 | 0.17 |
| Atherosclerosis | 0.2 | 1.3 | -5.5 |
| Atrial fibrillation | 2.6 | 1.2 | 1.17 |
| Autism | 6.6 | 6.6 | 0 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 0.2 | 0.6 | -2 |
| Carcinoma | 2 | 1.5 | 0.33 |
| Celiac Disease | 1.5 | 1.8 | -0.2 |
| Cerebral Palsy | 0.2 | 1.1 | -4.5 |
| Chronic Fatigue Syndrome | 4 | 4.7 | -0.18 |
| Chronic Kidney Disease | 2.8 | 2.1 | 0.33 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 1 | -0.43 |
| Chronic Urticaria (Hives) | 0.2 | 1.2 | -5 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.9 | -1.25 |
| Colorectal Cancer | 1.9 | 0.7 | 1.71 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 1.6 | 0.6 | 1.67 |
| COVID-19 | 6.6 | 10.6 | -0.61 |
| Crohn's Disease | 5 | 5.1 | -0.02 |
| cystic fibrosis | 0.6 | -0.6 | |
| deep vein thrombosis | 0.4 | -0.4 | |
| Depression | 6.7 | 5.7 | 0.18 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.9 | 1.2 | -0.33 |
| Endometriosis | 1.6 | 0.5 | 2.2 |
| Epilepsy | 1.9 | 1.7 | 0.12 |
| Fibromyalgia | 2.3 | 2.3 | 0 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 3 | 0.27 |
| gallstone disease (gsd) | 1 | 0.3 | 2.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 1 | 0.6 |
| Generalized anxiety disorder | 1.4 | 0.6 | 1.33 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.2 | -0.2 | |
| Graves' disease | 0.9 | 1.2 | -0.33 |
| Halitosis | 0.4 | 0.1 | 3 |
| Hashimoto's thyroiditis | 2.2 | 0.4 | 4.5 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.1 | 1.4 | 0.5 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 1.1 | -1.1 | |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | 0 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 1 | 2.2 | -1.2 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 0.6 | 0.6 | |
| IgA nephropathy (IgAN) | 4 | -4 | |
| Inflammatory Bowel Disease | 3.4 | 6.4 | -0.88 |
| Insomnia | 1 | 1.1 | -0.1 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1.1 | 0.2 | 4.5 |
| Irritable Bowel Syndrome | 1.2 | 3.3 | -1.75 |
| Liver Cirrhosis | 2 | 1.2 | 0.67 |
| Long COVID | 5.9 | 5.8 | 0.02 |
| Low bone mineral density | 1 | -1 | |
| Lung Cancer | 0.7 | -0.7 | |
| ME/CFS with IBS | 0.2 | 2.1 | -9.5 |
| ME/CFS without IBS | 2.3 | 1.5 | 0.53 |
| Metabolic Syndrome | 4.6 | 4.7 | -0.02 |
| Mood Disorders | 7.2 | 6 | 0.2 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | 0 |
| Multiple Sclerosis | 2.7 | 4.8 | -0.78 |
| Multiple system atrophy (MSA) | 0.4 | 0.4 | 0 |
| Neuropathy (all types) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.6 | 3.3 | -1.06 |
| Obesity | 5 | 2.8 | 0.79 |
| obsessive-compulsive disorder | 5.5 | 4.1 | 0.34 |
| Osteoarthritis | 1.8 | 1.8 | |
| Osteoporosis | 0.7 | 0.8 | -0.14 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 1.2 | 3.7 | -2.08 |
| Polycystic ovary syndrome | 2.1 | 0.3 | 6 |
| Postural orthostatic tachycardia syndrome | 0 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.7 | 0.3 | 1.33 |
| primary biliary cholangitis | 0.2 | 1.2 | -5 |
| Psoriasis | 2.2 | 2.1 | 0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 2 | 1.45 |
| Rosacea | 0.9 | 0.3 | 2 |
| Schizophrenia | 3 | 0.9 | 2.33 |
| scoliosis | 0.2 | 1 | -4 |
| Sjögren syndrome | 1.4 | 2.8 | -1 |
| Sleep Apnea | 0.6 | 1.6 | -1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 1.2 | 1.7 | -0.42 |
| Systemic Lupus Erythematosus | 3.4 | 1.2 | 1.83 |
| Tic Disorder | 1 | 1 | 0 |
| Tourette syndrome | 0.4 | -0.4 | |
| Type 1 Diabetes | 2.6 | 1.9 | 0.37 |
| Type 2 Diabetes | 5.5 | 5.1 | 0.08 |
| Ulcerative colitis | 1.6 | 3.6 | -1.25 |
| Unhealthy Ageing | 5.2 | 1.4 | 2.71 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.